6533b7d5fe1ef96bd1263c64

RESEARCH PRODUCT

GINA 2019: a fundamental change in asthma management

Helen K. ReddelAziz SheikhFanny W.s. KoAlvaro A. CruzAllan B. BeckerJ. Mark FitzgeraldLeonard B. BacharierGuy BrusselleHiromasa InoueEric D. BatemanJiangtao LinLouis-philippe BouletLouise FlemingSøren PedersenRoland BuhlMark L LevyArzu YorganciogluJerry A. Krishnan

subject

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescentMild asthmaGlobal HealthAsthma managementAdministration InhalationHumansMedicineAnti-Asthmatic AgentsDisease management (health)Monitoring PhysiologicRandomized Controlled Trials as TopicAsthmaInhalationbusiness.industryInhalerDisease Managementmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesBudesonide/formoterolPractice Guidelines as TopicFundamental changebusinessmedicine.drug

description

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.http://bit.ly/310LLzE

yearjournalcountryeditionlanguage
2019-06-01European Respiratory Journal
https://doi.org/10.1183/13993003.01046-2019